ArticleVaccines2024
MV140 Mucosal Vaccine Induces Targeted Immune Response for Enhanced Clearance of Uropathogenic
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study.Open forum infectious diseases · 2026Article
- Effectiveness of Non-Antibiotic Therapies in the Management of Recurrent Urinary Tract Infections in Women: A Systematic Review.International urogynecology journal · 2026Review
- Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine UromunePathogens (Basel, Switzerland) · 2025Review
- A Systematic Review of the Current Evidence of the Effectiveness and Safety of Immunoprophylaxis Using Sublingual Dead Whole Bacteria to Prevent Recurrent Urinary Tract Infections (rUTIs).Antibiotics (Basel, Switzerland) · 2025Review
- Current Scientific Advances in Vaccines Against UTIs: Challenges and Prospects.Microorganisms · 2025Review
- Uropathogenic Escherichia coli niche occupancy determines the effects of mucosal vaccine against FimH.Cell reports · 2025Article
- Evaluation of a bivalent vaccine composed of iron scavenger receptors PMI1426 and PMI1945 againstFuture microbiology · 2025Article
- Tissue-resident memory T cells in urinary tract diseases.Frontiers in immunology · 2025Review
- Sublingual MV140 vaccine: a promising noninvasive approach for recurrent urinary tract infections in women.Future microbiologyReview
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
MV140 is an inactivated whole-cell bacterial mucosal vaccine with proven clinical efficacy against recurrent urinary tract infections (UTIs). These infections are primarily caused by uropathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.